002900.SZ
Harbin Medisan Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 14.15
+2.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 813.2M | 789.4M | 1.1B | 1.2B | 1.0B |
| Cost of Revenue | 511.1M | 491.6M | 552.6M | 476.4M | 365.6M |
| Gross Profit | 302.1M | 297.8M | 579.9M | 710.4M | 662.8M |
| Operating Expenses | |||||
| R&D Expense | 88.0M | 93.2M | 105.2M | 112.8M | 89.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 200.0M | 207.6M | 169.9M | 176.4M | 140.7M |
| Selling & Marketing Expense | 289.2M | 280.3M | 262.2M | 421.8M | 453.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 609.3M | 611.3M | 552.9M | 721.7M | 693.2M |
| Cost and Expenses | 1.1B | 1.1B | 1.1B | 1.2B | 1.1B |
| Operating Income (EBIT) | (316.9M) | (345.1M) | 62.0M | 79.0M | 40.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (324.8M) | (353.0M) | 60.0M | 81.4M | 40.1M |
| Income Tax Expense | (5.3M) | (11.5M) | 5.0M | 11.3M | 13.6M |
| Bottom Line | |||||
| Net Income | (317.8M) | (339.6M) | 58.7M | 73.7M | 30.2M |
| Earnings from Cont. Ops | (319.5M) | (341.6M) | 55.0M | 70.1M | 26.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (317.8M) | (339.6M) | 58.7M | 73.7M | 30.2M |
| Per Share | |||||
| Basic EPS | (CN¥1.00) | (CN¥1.07) | CN¥0.19 | CN¥0.24 | CN¥0.10 |
| Diluted EPS | (CN¥1.00) | (CN¥1.07) | CN¥0.19 | CN¥0.24 | CN¥0.10 |
| Revenue Per Share | CN¥2.30 | CN¥2.49 | CN¥3.67 | CN¥3.87 | CN¥3.40 |
| Shares | |||||
| Basic Shares Outstanding | 352.8M | 317.4M | 308.8M | 306.9M | 302.1M |
| Diluted Shares Outstanding | 352.8M | 317.4M | 308.8M | 306.9M | 302.1M |
| Profitability Metrics | |||||
| EBITDA | — | (206.3M) | 168.1M | 182.8M | 141.3M |
| D&A | — | 138.8M | 106.1M | 103.8M | 100.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026